|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2C
|
|
pubmed:dateCreated |
2003-6-24
|
|
pubmed:abstractText |
Despite the fact that new drugs have emerged from clinical research in urothelial cancer during the last decade, the prognosis of patients with advanced disease remains poor with a median survival of 12 to 14 months. We designed a feasibility study of gemcitabine and oxaliplatin (GO) in patients with advanced urothelial cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1903-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12820476-Aged,
pubmed-meshheading:12820476-Aged, 80 and over,
pubmed-meshheading:12820476-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12820476-Carcinoma, Transitional Cell,
pubmed-meshheading:12820476-Deoxycytidine,
pubmed-meshheading:12820476-Drug Administration Schedule,
pubmed-meshheading:12820476-Humans,
pubmed-meshheading:12820476-Kidney Neoplasms,
pubmed-meshheading:12820476-Kidney Pelvis,
pubmed-meshheading:12820476-Male,
pubmed-meshheading:12820476-Middle Aged,
pubmed-meshheading:12820476-Organoplatinum Compounds,
pubmed-meshheading:12820476-Pilot Projects,
pubmed-meshheading:12820476-Ureteral Neoplasms,
pubmed-meshheading:12820476-Urinary Bladder Neoplasms,
pubmed-meshheading:12820476-Urologic Neoplasms
|
|
pubmed:articleTitle |
Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study.
|
|
pubmed:affiliation |
Department of Medical Oncology, C.R.L.C. Val d'Aurelle, Parc Euromédecine, 34598-Montpellier, France. stculine@valdorel.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
